Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma With PBRM1, SETD2, BAP1, or KDM5C Mutations

被引:5
|
作者
Liu, Yang [1 ]
Li, Yunhao [2 ]
Xu, Haimin [1 ]
Zhou, Luting [1 ,3 ]
Yang, Xiaoqun [1 ,3 ]
Wang, Chaofu [1 ,3 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Pathol, Sch Med, Shanghai, Peoples R China
[2] China Med Univ, Clin Coll 1, Shenyang, Peoples R China
[3] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Pathol, Number197,Ruijin Er Rd, Shanghai 200025, Peoples R China
基金
中国国家自然科学基金;
关键词
clear cell renal cell carcinoma; PBRM1; BAP1; KDM5C; SETD2; morphology;
D O I
10.1177/10668969231157317
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The last decade has seen great advances in genomic profiling and prognosis-associated factors of clear cell renal cell carcinoma (RCC), the most common entity in kidney cancer. Following VHL, PBRM1, SETD2, BAP1, and KDM5C have been validated as the most common co-occurring gene mutations in clear cell RCC by multicenter studies. However, the morphological features of clear cell RCC with co-occurring gene mutations remain unclear. In this study, we presented 20 clear cell RCCs that underwent next-generation sequencing, of which 1 tumor was reclassified as ELOC-mutated RCC. PBRM1, SETD2, BAP1, and KDM5C were the most common mutations, following VHL. Morphologically, clear cell RCC with PBRM1 or KDM5C mutation usually displayed a low-grade pattern. Cystic changes and hyalinized stroma were often observed. The Ki67 index was <10%. These observations indicated good prognosis. However, mutated SETD2 may increase the malignancy of clear cell RCC with PBRM1 mutation. Two clear cell RCCs with mutated PBRM1 and SETD2 developed local or distant metastases. Clear cell RCC with BAP1 mutations always had high-grade patterns, and rhabdoid differentiation was also observed, indicating that BAP1 mutation was associated with poor outcomes. Papillary architecture was often a feature of BAP1 mutation, which is uncommon in clear cell RCC. PDL1 was positive in only one tumor with BAP1 mutation, and the positivity rate was limited to 5%. B7H3 was negative in all tumors. Morphologic findings in this small cohort may suggest why PBRM1 mutation does not correlate with decreased survival, whereas BAP1 mutation usually predicts poor outcomes.
引用
收藏
页码:1485 / 1494
页数:10
相关论文
共 50 条
  • [31] Differential overall survival results in RECORD-3 study based on three distinct clear cell metastatic renal cell carcinoma molecular subgroups classified by BAP1 and/or PBRM1 mutations
    Hsieh, James
    Chen, David
    Wang, Patricia
    Chen, Ying-Bei
    Mahtab, Marker
    Pate, Parul
    Bhanot, Umesh
    Berger, Michael
    Cheng, Emily
    Knox, Jennifer
    Voss, Martin
    Voi, Maurizio
    Motzer, Robert
    BJU INTERNATIONAL, 2016, 118 : 10 - 10
  • [32] Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network
    Hakimi, A. Ari
    Ostrovnaya, Irina
    Reva, Boris
    Schultz, Nikolaus
    Chen, Ying-Bei
    Gonen, Mithat
    Liu, Han
    Takeda, Shugaku
    Voss, Martin H.
    Tickoo, Satish K.
    Reuter, Victor E.
    Russo, Paul
    Cheng, Emily H.
    Sander, Chris
    Motzer, Robert J.
    Hsieh, James J.
    CLINICAL CANCER RESEARCH, 2013, 19 (12) : 3259 - 3267
  • [33] Angiogenic and T-effector subgroups identified by gene expression profiling (GEP) and propensity for PBRM1 and BAP1 alterations in clear cell renal cell carcinoma (ccRCC).
    Barata, Pedro C.
    Gulati, Shuchi
    Elliott, Andrew
    Rao, Arpit
    Hammers, Hans J.
    Quinn, David I.
    Gartrell, Benjamin Adam
    Zibelman, Matthew R.
    Wei Shuanzeng
    Geynisman, Daniel M.
    Zhang Tian
    Darabi, Sourat
    Dawson, Nancy Ann
    Hauke, Ralph J.
    Poorman, Kelsey Anne
    Nabhan, Chadi
    Ryan, Charles J.
    Heath, Elisabeth I.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [34] EXPRESSION OF SETD2 COMBINED WITH PBRM1 AS PROGNOSTIC PREDICTOR IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA RECEIVING TYROSINE KINASE INHIBITOR
    Cai, Wen
    Huang, Jiwei
    Wang, Zaoyu
    Yuan, Yichu
    Kong, Wen
    Zhang, Jin
    Chen, Yonghui
    Liu, Qiang
    Xue, Wei
    Huang, Yiran
    JOURNAL OF UROLOGY, 2019, 201 (04): : E72 - E73
  • [35] Exome Sequencing Shows BAP1 and PBRM1 Are Recurring Somatic Mutations in Biphenotypic Liver Carcinoma
    Sehn, J. K.
    Chapman, W. C.
    Tan, B. R.
    Brunt, E. M.
    MODERN PATHOLOGY, 2014, 27 : 428A - 428A
  • [36] Exome Sequencing Shows BAP1 and PBRM1 Are Recurring Somatic Mutations in Biphenotypic Liver Carcinoma
    Sehn, J. K.
    Chapman, W. C.
    Tan, B. R.
    Brunt, E. M.
    LABORATORY INVESTIGATION, 2014, 94 : 428A - 428A
  • [37] Concordance of BAP1, PBRM1, Ki-67, and TOPOIIa protein expression in primary clear cell renal cell carcinoma tumors and patient-matched metastatic tumors
    Eckel-Passow, Jeanette E.
    Serie, Daniel J.
    Cheville, John C.
    Ho, Thai H.
    Harrington, Sue M.
    Hilton, Tracy
    Lohse, Christine
    Shreders, Amanda
    Kapur, Payal
    Brugarolas, James
    Thompson, R. Houston
    Leibovich, Bradley C.
    Kwon, Eugene D.
    Joseph, Richard W.
    Parker, Alexander S.
    CLINICAL CANCER RESEARCH, 2016, 22
  • [38] Bap1 and Pbrm1: Determinants of Tumor Grade and mTOR Activation in VHL-Deficient Mouse Models of Renal Cell Carcinoma
    Leung, Janet Y.
    Kim, William Y.
    CANCER DISCOVERY, 2017, 7 (08) : 802 - 804
  • [39] Morphological characteristics of SETD2-mutated locally advanced clear cell renal cell carcinoma: Comparison with BAP1-mutated clear cell renal cell carcinoma
    Takeda, Kotaro
    Bastacky, Sheldon
    Dhir, Rajiv
    Mohebnasab, Maedeh
    Quiroga-Garza, Gabriela M.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2024, 68
  • [40] Identifying BAP1 Mutations in Clear-Cell Renal Cell Carcinoma by CT Radiomics: Preliminary Findings
    Feng, Zhan
    Zhang, Lixia
    Qi, Zhong
    Shen, Qijun
    Hu, Zhengyu
    Chen, Feng
    FRONTIERS IN ONCOLOGY, 2020, 10